Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: Structural insights for better antiviral therapy

Journal of Virology

Volumn 77, Issue 2, 2003, Pages 1306-1315

  Prabu Jeyabalan, Moses ^a   Nalivaika, Ellen A ^a   King, Nancy M ^a   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; PROTEIN PROTEIN INTERACTION; VIRUS STRAIN;

HIV PROTEASE; HIV PROTEASE INHIBITORS; HYDROGEN BONDING; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037223718     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.2.1306-1315.2003     Document Type: Article

References (66)

1. Baldwin, E. T., T. N. Bhat, B. Liu, N. Pattabiraman, and J. W. Erickson. 1995. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat. Struct. Biol. 2:244-249.
2. Boden, D., and M. Markowitz. 1998. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 42:2775-2783.
3. Brunger, A. T. 1992. The free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 355:472-474.
4. Brunger, A. T. 1991. Simulated annealing in crystallography. Annu. Rev. Phys. Chem. 42:197-223.
5. Brunger, A. T., P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, Kuszewski, J., M. Nilges, N. S. Pannu, R. J. Read, L. M. Rice, T. Simonson, and G. L. Warren. 1998. Crystallography & NMR System: A new software suite for macromolecular structure determination. Acta Crystallogr. D54:905-921.
6. Brunger, A. T., A. Krukowski, and J. Erickson. 1990. Slow-cooling protocols for crystallographic refinement by simulated annealing. Acta Crystallogr. A46:585-593.
7. Chen, Z., Y. Li, E. Chen, D. L. Hall, P. L. Darke, C. Culberson, J. A. Shafer, and L. C. Kuo. 1994. Crystal structure at 1.9-Å resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J. Biol. Chem. 269:26344-26348.
8. Chou, K.-C., A. G. Tomasselli, I. M. Reardon, and R. L. Heinrickson. 1996. Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method. Proteins 24:51-72.
9. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
10. Deeks, S. G., R. M. Grant, G. W. Beatty, C. Horton, J. Detmer, and S. Eastman. 1998. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS Res. Hum. Retroviruses 12:F97-F102.
11. Dunn, B. M., A. Gustchina, A. Wlodawer, and J. Kay. 1994. Subsite preferences of retroviral proteinases. Methods Enzymol. 241:254-278.
12. Eastman, P. S., J. Mittler, R. Kelso, C. Gee, E. Boyer, J. Kolberg, M. Urdea, J. M. Leonard, D. W. Norbeck, H. Mo, and M. Markowitz. 1998. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J. Virol. 72:5154-5164.
13. Engh, R. A., and R. Huber. 1991. Accurate bond and angle parameters for X-ray protein-structure refinement. Acta Crystallogr. A47:392-400.
14. Erickson, J. W., and K. B. Stanley. 1996. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36:545-571.
15. Ermolieff, J., X. Lin, and J. Tang. 1997. Kinetic properties of saquinavirresistant mutants of human immunodeficiency virus type I protease and their implications in drug resistance in vivo. Biochemistry. 36:12364-12370.
16. Flexner, C. 1998. HIV-protease inhibitors. N. Engl. J. Med. 338:1281-1292.
17. Forstenlehner, M. 2000. AIDS: New FDA approved agents AIDS. Pharm. Unserer Zeit 29:58.
18. Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34: 9282-9287.
19. Henderśon, L. E., T. D. Copeland, R. C. Sowder, A. M. Schultz, and S. Oraszlan. 1988. Human Retroviruses, Cancer and AIDS: Approaches to Prevention and Therapy. Alan R. Liss, New York, N.Y.
20. Hendrickson, W. A., and J. H. Konnert. 1980. In R. Diamond, S. Ramaseshan, and K. Venkatesan (ed.), Computing in Crystallography, p. 13.01-13.23. Indian Academy of Sciences, Bangalore, India.
21. Hui, J. O., A. G. Tomasselli, I. M. Reardon, J. M. Lull, D. P. Brunner, C.-S. C. Tomich, and R. L. Heinrikson. 1993. Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies. J. Protein Chem. 12:323-327.
22. Ji, J. P., and L. A. Loeb. 1992. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry 31:954-958.
23. Kaldor, S. W., V. J. Kalish, J. F. Davies, Jr., B. V. Shetty, J. E. Fritz, K. Appelt, J. A. Burgess, K. M. Campanale, N. Y. Chirgadze, D. K. Clawson, B. A. Dressman, S. D. Hatch, D. A. Khalil, M. B. Kosa, P. P. Lubbehusen, M. A. Muesing, A. K. Patick, S. H. Reich, K. S. Su, and J. H. Tatlock. 1997. Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:3979-3985.
24. Kemf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, N. L. Fino, C. H. Park, X. P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, L. Sham, T. Robins, D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
25. Kim, E. E., C. T. Baker, M. D. Dwyer, M. A. Murcko, B. G. Roa, R. D. Tung, and M. A. Navia. 1995. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J. Am. Chem. Soc. 117:1181.
26. King, N. M., L. Melnick, M. Prabu-Jeyabalan, E. A. Nalivaika, S.-S. Yang, Y. Gao, X. Nie, C. Zepp, D. L. Heefner, and C. A. Schiffer. 2002. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci. 11:418-429.
27. Klabe, R. M., L. T. Bacheler, P. J. Ala, S. Erickson-Viitanen, and J. L. Meek. 1998. Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency. Biochemistry 37:8735-8742.
28. Kleywegt, G. J. 2000. Validation of protein crystal structures. Acta Crystallogr. D56:249-265.
29. Kleywegt, G. J., and T. A. Jones. 1995. Where freedom is given liberties are taken. Structure 3:535-540.
30. Lawrence, M. G., and P. M. Colman. 1993. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234:946-950.
31. Lee, B., and F. M. Richards. 1971. The interpretation of protein structures: Estimation of static accessibility. J. Mol. Biol. 55:379-400.
32. Lin, Y., X. Lin, L. Hong, S, Foundling, R. L. Heinrikson, S. Thaisrivongs, W. Leelamanit, D. Raterman, M. Shah, B. M. Dunn, and J. Tang. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type I protease: Relationship to drug resistance. Biochemistry 34:1143-1152.
33. Mahalingam, B., J. Louis, C. Reed, J. Adomat, J. Krouse, Y. Wang, R. Harrison, and I. T. Weber. 1999. Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur. J. Biochem. 263:238-245.
34. Mahalingam, B., J. M. Louis, J. Hung, R. W. Harrison, and I. T. Weber. 2001. Structural implications of drug-resistant mutants of HIV-1 protease: High-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 43:455-464.
35. Martin, J. L., J. Begun, A. Schindeler, W. A. Wickramasinghe, D. Alewood, P. F. Alewood, D. A. Bergman, R. I. Brinkworth, G. Abbenante, D. R. March, R. C. Reid, and D. P. Fairlie. 1999. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. Biochemistry 38:7978-7988.
36. McDonald, C. K., and D. R. Kuritkzkes. 1997. Human immunodeficiency virus type 1 protease inhibitors. Arch. Intern. Med. 157:951-959.
37. Minor, W. 1993. XDISPLAYF Program. Purdue University, West Lafayette, Ind.
38. Molla, A., G. R. Granneman, E. Sun, and D. J. Kempf. 1998. Recent developments in HIV protease inhibitor therapy. Antiviral Res. 39:1-23.
39. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
40. Nicholls, A., K. Sharp, and B. Honig. 1991. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11:281-296.
41. a. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
42. Pazhanisamy, S., C. M. Stuver, A. B. Cullinan, N. Margolin, B. G. Rao, and D. J. Livingston. 1996. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 271:17979-17985.
43. Pettit, S. C., N. Sheng, R. Tritch, S. Erickson-Viitanen, and R. Swanstrom. 1998. The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv. Exp. Med. Biol. 436:15-25.
44. Prabu-Jeyabalan, M., E. Nalivaika, and C. A. Schiffer. 2000. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J. Mol. Biol. 301:1207-1220.
45. Prabu-Jeyabalan, P., E. Nalivaika, and C. A. Schiffer. 2002. Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes. Structure 10:369-381.
46. Ridky, T., and J. Leis. 1995. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270:29621-29623.
47. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1988. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
48. Roberts, J. D., B. D. Preston, and L. A. Johnston. 1989. Fidelity of two retroviral reverse transcriptases during DNA-dependent DNA synthesis in vitro. Mol. Cell. Biol. 9:469-476.
49. Rosé, J. R., L. M. Babe., and C. S. Craik. 1995. Defining the level of human immunodeficiency virus type (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J. Virol. 69:2751-2758.
50. Rosé, R. B., C. S. Craik, N. L. Douglas, and R. M. Stroud. 1996. Threedimensional structures of HIV-1 and SIV protease product complexes. Biochemistry 35:12933-12944.
51. Sack, J. S. 1988. CHAIN - A crystallographic modeling program. J. Mol. Graphics 6:224-225.
52. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News 5:129-142.
53. Schock, H. B., V. M. Garsky, and L. C. Kuo. 1996. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. J. Biol. Chem. 271:31957-31963.
54. Scott, W. R., and C. A. Schiffer. 2000. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Struct. Fold. Des. 8:1259-1265.
55. Shafer, R. W., D. Stevenson, and B. Chan. 1999. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 27:348-352.
56. Spinelli, S., Q. Liu, Z., P. M. Alzari, P. H. Hirel, and R. J. Poljak. 1991. The three-dimensional structure of the aspartyl protease from the HIV-1 isolate BRU. Biochemie 73:1391-1396.
57. Swanstrom, R., and J. Eron. 2000. Human immunodeficiency virus type-1 protease inhibitors: Therapeutic successes and failures, supression and resistance. Pharmacol. Ther. 86:145-170.
58. Thanki, N., J. K. M. Rao, S. I. Foundling, J. Howe, J. B. Moon, J. O. Hui, A. G. Tomasselli, R. L. Heinrikson, S. Thaisrivongs, and A. Wlodawer. 1992. Crystal structure of a complex of HIV-1 protease with dihydroxyethylenecontaining inhibitor: Comparisons with molecular modeling. Protein Sci. 1:1061-1072.
59. Tozser, J., I. Blaha, T. D. Copeland, E. M. Wondrak, and S. Oroszlan. 1991. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 281:77-80.
60. Vacca, J. P., B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Hollloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff. 1994. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
61. Weber, I. T., J. Wu, J. Adomat, R. W. Harrison, A. R. Kimmel, E. M. Wondrak, and J. M. Louis. 1997. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate-interactions with frequently occurring glutamic acid residue at P2′ position of substrates. Eur. J Biochem. 249:523-530.
62. Williams, T., and C. Kelley. 1998. GNUPLOT © 1986-1993, 1998 (contact for further information http://www.gnuplot.info).
63. Wlodawer, A., and J. W. Erickson. 1993. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62:543-585.
64. Wlodawer, A., and A. Gustchina. 2000. Structural and biochemical studies of retroviral proteases. Biochim. Biophys. Acta 1477:16-34.
65. Wlodawer, A., M. Miller, B. K. Sathyanarayana, E. Baldwin, I. T. Weber, L. M. Selk, L. Clawson, J. Schneider, and S. B. Kent. 1989. Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 245:616-621.
66. Zhang, Y., H. Qian, Z. Love, and E. Barklis. 1998. Analysis of the assembly function of the human immunodeficiency virus type 1 gag protein nucleocapsid domain. J. Virol. 72:1782-1789.